文献速递胸部肿瘤

Avelumab对比多西他赛治疗铂类经治晚期NSCLC:JAVELIN Lung 200 III期试验2年随访

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
PubMed 文献 · J Thorac Oncol · 2021-04-09

JAVELIN Lung 200 III期试验中,avelumab对比多西他赛在铂类经治PD-L1阳性晚期NSCLC中未显著延长总生存。本次报告大于2年随访数据:PD-L1阳性人群2年OS率分别为29.9%与20.5%;PD-L1≥50%和≥80%亚组中avelumab的2年OS率约为多西他赛的两倍。

要点

  • PD-L1阳性人群2年OS率avelumab组29.9%,多西他赛组20.5%。
  • PD-L1≥50%亚组2年OS率36.4% vs 17.7%,≥80%亚组40.2% vs 20.3%。
  • 中位缓解持续时间avelumab组19.1个月,多西他赛组5.7个月。

核心结论

  • JAVELIN Lung 200主要分析显示avelumab未显著延长PD-L1阳性铂类经治NSCLC的总生存,但2年随访的事后分析显示在高PD-L1表达亚组中avelumab的2年OS率翻倍。

研究设计与样本

  • III期JAVELIN Lung 200试验随机入组792例铂类双药化疗后进展的IIIB/IV期或复发NSCLC患者,1:1接受avelumab 10 mg/kg每2周或docetaxel 75 mg/m2每3周。
  • 主要终点为PD-L1阳性(≥1%肿瘤细胞表达,IHC 73-10 pharmDx法)患者的总生存。
  • PD-L1阳性人群共529例,avelumab组264例,多西他赛组265例。

主要发现

  • 截至2019年3月4日,PD-L1阳性人群avelumab组中位OS随访35.4个月,多西他赛组34.7个月;研究治疗仍在进行者分别为25例(9.5%)和0例。
  • PD-L1阳性人群2年OS率(95%CI)avelumab组29.9%(24.5%-35.5%),多西他赛组20.5%(15.6%-25.8%)。
  • PD-L1≥50%亚组2年OS率avelumab组36.4%(29.1%-43.7%),多西他赛组17.7%(11.8%-24.7%)。
  • PD-L1≥80%亚组2年OS率avelumab组40.2%(31.3%-49.0%),多西他赛组20.3%(12.9%-28.8%)。
  • 研究者评估的中位缓解持续时间avelumab组19.1个月(95%CI 10.8-34.8),多西他赛组5.7个月(95%CI 4.1-8.3)。

关键数值与推荐

  • PD-L1阳性定义:≥1%肿瘤细胞表达,采用IHC 73-10 pharmDx assay检测。
  • avelumab剂量10 mg/kg每2周,多西他赛75 mg/m2每3周。

临床怎么用

  • 对于铂类经治的PD-L1高表达(≥50%或≥80%)晚期NSCLC患者,avelumab的2年生存率约为多西他赛的两倍,可作为潜在治疗选择参考。
  • avelumab组中位缓解持续时间较多西他赛延长,提示免疫治疗可能带来更持久的获益。

局限性

  • 2年随访的亚组分析为事后分析,未提供正式统计检验结果。
  • 主要分析未显示avelumab对比多西他赛显著延长OS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data. METHODS: Patients with stage IIIB or IV or recurrent NSCLC with disease progression after platinum-doublet chemotherapy were randomized 1:1 to avelumab 10 mg/kg every 2 weeks or docetaxel 75 mg/m2 every 3 weeks. The primary end point was OS in patients with PD-L1+ tumors (greater than or equal to 1% tumor cell expression; IHC 73-10 pharmDx assay). RESULTS: Of 792 patients, 529 had PD-L1+ tumors (264 versus 265 in the avelumab versus docetaxel arms, respectively). As of March 4, 2019, median duration of follow-up for OS in the PD-L1+ population was 35.4 months in the avelumab arm and 34.7 months in the docetaxel arm; study treatment was ongoing in 25 (9.5%) versus 0 patients, respectively. In the PD-L1+ population, 2-year OS rates (95% confidence interval [CI]) with avelumab versus docetaxel were 29.9% (24.5%-35.5%) versus 20.5% (15.6%-25.8%); in greater than or equal to 50% PD-L1+ subgroups, 2-year OS rates were 36.4% (29.1%-43.7%) versus 17.7% (11.8%-24.7%) and in the greater than or equal to 80% subgroup were 40.2% (31.3%-49.0%) versus 20.3% (12.9%-28.8%), respectively. Median duration of response (investigator assessed) was 19.1 months (95% CI: 10.8-34.8) versus 5.7 months (95% CI: 4.1-8.3). Safety profiles for both arms were consistent with the primary analysis. CONCLUSIONS: Although the JAVELIN Lung 200 primary analysis (reported previously) revealed that avelumab did not significantly prolong OS versus docetaxel in patients with platinum-treated PD-L1+ NSCLC, posthoc analyses at 2 years of follow-up revealed that 2-year OS rates were doubled with avelumab in subgroups with higher PD-L1 expression (greater than or equal to 50% and greater than or equal to 80%).

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Park K, Özgüroğlu M, Vansteenkiste J, et al. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. J Thorac Oncol. 2021. PMID: 33845211. doi:10.1016/j.jtho.2021.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。